Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK, safety and tolerability of single-dose SAR442970 in healthy Japanese adults
jRCT2071230056Phase 1Completed
- Sponsor
- Sanofi
- Start
- Sep 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brivekimig (2 arms), sponsored by Sanofi. Primary endpoints: Cmax, AUClast and 1 more. Started Sep 2023; status: completed.
02
Drugs
brivekimig
Beyond the preview
Go deeper on jRCT2071230056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230056.